Published in Dermatology Journal Scan / Research · March 22, 2022 Chemoprevention of Cutaneous Squamous Cell Carcinoma in Solid Organ Transplant Recipients Using Topical Sirolimus Journal of the American Academy of Dermatology

TAKE-HOME MESSAGE

• In this study, solid organ transplant recipients (not on systemic sirolimus) with history of nonmelanoma skin cancer were treated on one arm and dorsal hand with topical sirolimus and the other arm and dorsal hand with control vehicle for 5 weeks. The number of keratotic lesions decreased in the treated arm by 31% compared with a 6% increase in the control arm. At 24-month follow-up, the treated side demonstrated 81% reduction in intraepithelial neoplasms but not a statistical difference in squamous cell carcinomas.

• Topical sirolimus may decrease the burden of keratotic lesions and intraepithelial neoplasms in solid organ transplant recipients.

–  Kelly B. Scarberry, MD

Abstract

Immunosuppression in solid organ transplant recipients (SOTR) greatly increases the risk of keratinocyte cancer (KC), indisputably a significant burden in terms of morbidity, mortality and cost. Switching calcineurin inhibitors to sirolimus is a major strategy that has resulted in a two-fold reduction in the risk of SCC, but is poorly tolerated with many serious adverse events.

Journal of the American Academy of Dermatology

Chemoprevention of cutaneous squamous cell carcinoma and its precursors in solid organ transplant recipients using topical sirolimus: a randomized, double-blind, placebo-controlled pilot trial

J Am Acad Dermatol 2022 Feb 24;[EPub Ahead of Print], S Chong, HY Wong, A Althabteh, C Cox, P Stevenson, S Brown, A Griffin, N Isbel, G Siller, HP Soyer, H Schaider, E Roy, S Campbell, AC Green, K Khosrotehrani 

Sent from my iPhone

Benjamin Hidalgo-Matlock
Skin Care Physicians of Costa Rica

Clinica Victoria en San Pedro: 4000-1054
Momentum Escazu: 2101-9574

Please excuse the shortness of this message, as it has been sent from
a mobile device.